315 related articles for article (PubMed ID: 23280874)
61. Induction of carbohydrate-specific antibodies in HLA-DR transgenic mice by a synthetic glycopeptide: a potential anti cancer vaccine for human use.
Vichier-Guerre S; Lo-Man R; BenMohamed L; Dériaud E; Kovats S; Leclerc C; Bay S
J Pept Res; 2003 Sep; 62(3):117-24. PubMed ID: 12895273
[TBL] [Abstract][Full Text] [Related]
62. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
[TBL] [Abstract][Full Text] [Related]
63. Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope.
Lu Y; Ouyang K; Fang J; Zhang H; Wu G; Ma Y; Zhang Y; Hu X; Jin L; Cao R; Fan H; Li T; Liu J
Vaccine; 2009 Aug; 27(39):5411-8. PubMed ID: 19616501
[TBL] [Abstract][Full Text] [Related]
64. Large-scale synthesis and structural analysis of a synthetic glycopeptide dendrimer as an anti-cancer vaccine candidate.
Ganneau C; Simenel C; Emptas E; Courtiol T; Coïc YM; Artaud C; Dériaud E; Bonhomme F; Delepierre M; Leclerc C; Lo-Man R; Bay S
Org Biomol Chem; 2016 Dec; 15(1):114-123. PubMed ID: 27812586
[TBL] [Abstract][Full Text] [Related]
65. Rational design and immunogenicity of liposome-based diepitope constructs: application to synthetic oligosaccharides mimicking the Shigella flexneri 2a O-antigen.
Said Hassane F; Phalipon A; Tanguy M; Guerreiro C; Bélot F; Frisch B; Mulard LA; Schuber F
Vaccine; 2009 Aug; 27(39):5419-26. PubMed ID: 19559116
[TBL] [Abstract][Full Text] [Related]
66. Enhancement of the immunogenicity of synthetic carbohydrate vaccines by chemical modifications of STn antigen.
Yang F; Zheng XJ; Huo CX; Wang Y; Zhang Y; Ye XS
ACS Chem Biol; 2011 Mar; 6(3):252-9. PubMed ID: 21121644
[TBL] [Abstract][Full Text] [Related]
67. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
[TBL] [Abstract][Full Text] [Related]
68. Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design.
Beckwith DM; Cudic M
Semin Immunol; 2020 Feb; 47():101389. PubMed ID: 31926647
[TBL] [Abstract][Full Text] [Related]
69. Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors.
Ingale S; Wolfert MA; Buskas T; Boons GJ
Chembiochem; 2009 Feb; 10(3):455-63. PubMed ID: 19145607
[TBL] [Abstract][Full Text] [Related]
70. Heterovalent Glycodendrimers as Epitope Carriers for Antitumor Synthetic Vaccines.
Pifferi C; Thomas B; Goyard D; Berthet N; Renaudet O
Chemistry; 2017 Nov; 23(64):16283-16296. PubMed ID: 28845889
[TBL] [Abstract][Full Text] [Related]
71. O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma.
Stepensky D; Tzehoval E; Vadai E; Eisenbach L
Clin Exp Immunol; 2006 Jan; 143(1):139-49. PubMed ID: 16367945
[TBL] [Abstract][Full Text] [Related]
72. Reduced Breast Tumor Growth after Immunization with a Tumor-Restricted MUC1 Glycopeptide Conjugated to Tetanus Toxoid.
Stergiou N; Gaidzik N; Heimes AS; Dietzen S; Besenius P; Jäkel J; Brenner W; Schmidt M; Kunz H; Schmitt E
Cancer Immunol Res; 2019 Jan; 7(1):113-122. PubMed ID: 30413430
[TBL] [Abstract][Full Text] [Related]
73. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat.
Tarp MA; Sørensen AL; Mandel U; Paulsen H; Burchell J; Taylor-Papadimitriou J; Clausen H
Glycobiology; 2007 Feb; 17(2):197-209. PubMed ID: 17050588
[TBL] [Abstract][Full Text] [Related]
74. Cytotoxic T lymphocyte response induced by an improved synthetic lipopeptide vaccine against cervical cancer.
Xu DH; Zhou CH; Xia YP; Qiu ZY; Wu YZ; Jia ZC; Zhou W
Acta Pharmacol Sin; 2007 May; 28(5):695-702. PubMed ID: 17439726
[TBL] [Abstract][Full Text] [Related]
75. Design of three-component vaccines against group A streptococcal infections: importance of spatial arrangement of vaccine components.
Abdel-Aal AB; Zaman M; Fujita Y; Batzloff MR; Good MF; Toth I
J Med Chem; 2010 Nov; 53(22):8041-6. PubMed ID: 21028828
[TBL] [Abstract][Full Text] [Related]
76. A universal anti-HIV-1 Tat epitope vaccine that is fully synthetic and self-adjuvanting.
Goldstein G; Chicca JJ
Vaccine; 2010 Jan; 28(4):1008-14. PubMed ID: 19931501
[TBL] [Abstract][Full Text] [Related]
77. Branched and linear lipopeptide vaccines have different effects on primary CD4+ and CD8+ T-cell activation but induce similar tumor-protective memory CD8+ T-cell responses.
Baz A; Buttigieg K; Zeng W; Rizkalla M; Jackson DC; Groves P; Kelso A
Vaccine; 2008 May; 26(21):2570-9. PubMed ID: 18420312
[TBL] [Abstract][Full Text] [Related]
78. Immunotherapy for cancer: synthetic carbohydrate-based vaccines.
Buskas T; Thompson P; Boons GJ
Chem Commun (Camb); 2009 Sep; (36):5335-49. PubMed ID: 19724783
[TBL] [Abstract][Full Text] [Related]
79. Synthesis and biological evaluation of an anticancer vaccine containing the C-glycoside analogue of the Tn epitope.
Peri F; Cipolla L; Rescigno M; La Ferla B; Nicotra F
Bioconjug Chem; 2001; 12(3):325-8. PubMed ID: 11353527
[TBL] [Abstract][Full Text] [Related]
80. Synthetic vaccines from tumor-associated glycopeptide antigens.
Westerlind U; Kunz H
Chimia (Aarau); 2011; 65(1-2):30-4. PubMed ID: 21469441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
